Data from Transcriptomics and Transposon Mutagenesis Identify Multiple Mechanisms of Resistance to the FGFR Inhibitor AZD4547

Abstract

<div>Abstract<p>In human cancers, FGFR signaling is frequently hyperactivated by deregulation of FGF ligands or by activating mutations in the FGFR receptors such as gene amplifications, point mutations, and gene fusions. As such, FGFR inhibitors are considered an attractive therapeutic strategy for patients with mutations in FGFR family members. We previously identified <i>Fgfr2</i> as a key driver of invasive lobular carcinoma (ILC) in an <i>in vivo</i> insertional mutagenesis screen using the <i>Sleeping Beauty</i> transposon system. Here we explore whether these FGFR-driven ILCs are sensitive to the FGFR inhibitor AZD4547 and use transposon mutagenesis in these tumors to identify potential mechanisms of resistance to therapy. Combined with RNA sequencing-based analyses of AZD4547-resistant tumors, our <i>in vivo</i> approach identified several known and novel potential resistance mechanisms to FGFR inhibition, most of which converged on reactivation of the canonical MAPK–ERK signaling cascade. Observed resistance mechanisms included mutations in the tyrosine kinase domain of FGFR2, overexpression of MET, inactivation of RASA1, and activation of the drug-efflux transporter ABCG2. ABCG2 and RASA1 were identified only from <i>de novo</i> transposon insertions acquired during AZD4547 treatment, demonstrating that insertional mutagenesis in mice is an effective tool for identifying potential mechanisms of resistance to targeted cancer therapies.</p><p><b>Significance:</b> These findings demonstrate that a combined approach of transcriptomics and insertional mutagenesis <i>in vivo</i> is an effective method for identifying potential targets to overcome resistance to therapy in the clinic. <i>Cancer Res; 78(19); 5668–79. ©2018 AACR</i>.</p></div>